Galderma to buy ZO Skin Health for $1.5 billion to strengthen dermatology portfolio. Galderma has signed an agreement to buy physician-dispensed brand ZO Skin Health to expand its dermatological ​skin care offering in ‘the fast-growing medical-grade skin care segment’. Galderma is set to acquire ZO Skin Health for US$1.5bn to bolster its position in the medical-grade skin care segment. ZO Skin Health will join Galderma’s portfolio, which spans injectable aesthetics, dermatological skin care and therapeutic dermatology, “strengthening” its offering in an area the company already has “significant opportunities” in. Galderma’s deal to acquire 100% of ZO Skin Health is expected to close in the fourth quarter of 2026, or early 2027, subject to regulatory approvals and other customary closing conditions. The Switzerland-based company said ZO Skin Health will join its flagship brands Cetaphil and Alastin in Galderma’s dermatological skin care portfolio, supporting its position as “a partner of choice” for dermatologists, plastic surgeons and aesthetic professionals.